XmAb564, A NOVEL POTENCY-REDUCED IL-2 FC FUSION PROTEIN SELECTIVELY EXPANDS REGULATORY T CELLS: RESULTS FROM A SINGLE ASCENDING DOSE STUDY IN HEALTHY ADULT VOLUNTEERS

被引：0

作者：

Clynes, R. ^{[1
]}

Key, C. ^{[2
]}

Ding, Y. ^{[3
]}

Li, L. ^{[4
]}

Woo, J. ^{[1
]}

Sadler, B. ^{[5
]}

Kanodia, J. ^{[6
]}

Sun, H. ^{[3
]}

Zitnik, R. ^{[7
]}

机构：

[1] Xencor Inc, Translat Biol, Monrovia, CA USA

[2] ICON Inc, Early Phase Serv, San Antonio, TX USA

[3] Xencor Inc, Bioinformat, Monrovia, CA USA

[4] Xencor Inc, Biometr, Monrovia, CA USA

[5] ICON Inc, Quantitat Pharmacol & Pharmacometr, San Antonio, TX USA

[6] Xencor Inc, Clin Syst & Pharmacol, Monrovia, CA USA

[7] Xencor, Clin Dev, Monrovia, CA USA

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2023年 / 82卷

关键词：

Systemic lupus erythematosus; Randomized control trial; Biomarkers;

D O I：

10.1136/annrheumdis-2023-eular.2868

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

POS0119

引用

页码：275 / 275

页数：1

共 8 条

[1] EFAVALEUKIN ALFA, A NOVEL IL-2 MUTEIN, SELECTIVELY EXPANDS REGULATORY T CELLS IN PATIENTS WITH SLE: FINAL RESULTS OF A PHASE 1B MULTIPLE ASCENDING DOSE STUDY
Tchao, N.
Sarkar, N.
Hu, X.
Zhang, R.
Milmont, C.
Jin, Y. Shi
Chow, V.
Kroenke, M.
Gorski, K.
Furie, R.
Kivitz, A.
Cohen, S.
ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 1343 - 1344
[2] Efavaleukin Alfa, a Novel IL-2 Mutein, Selectively Expands Regulatory T Cells in Patients with SLE: Interim Results of a Phase 1b Multiple Ascending Dose Study
Tchao, Nadia
Amouzadeh, Hamid
Sarkar, Nandita
Chow, Vincent
Hu, Xuguang
Kroenke, Mark
Wang, Hui
Zhang, Rong
Gorski, Kevin
Furie, Richard
Kivitz, Alan
Cohen, Stanley
ARTHRITIS & RHEUMATOLOGY, 2021, 73 : 3613 - 3615
[3] A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells
Lin, Yuan
Wang, Xue
Qin, Yuhao
Wang, Chengpan
Zhou, Tang
Zhang, Long
Su, Lu
Ren, Wenming
Liao, Cheng
COMMUNICATIONS BIOLOGY, 2024, 7 (01)
[4] A single-agent fusion of human IL-2 and anti-IL-2 antibody that selectively expands regulatory T cells
Yuan Lin
Xue Wang
Yuhao Qin
Chengpan Wang
Tang Zhou
Long Zhang
Lu Su
Wenming Ren
Cheng Liao
Communications Biology, 7
[5] SAFETY, TOLERABILITY AND SELECTIVE EXPANSION OF REGULATORY T CELLS BY A SINGLE DOSE OF THE NOVEL IL-2 MUTEIN PT101 IN A PHASE 1 STUDY IN HEALTHY VOLUNTEERS
Sundy, J. S.
Otipoby, K. L.
Higginson-Scott, N.
Visweswaraiah, J.
Sampson, E.
Kis-Toth, K.
Monsef, A.
Petaipimol, P.
Essayan, D.
Cosenza, M. E.
Kakkar, R.
Viney, J.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1167 - 1167
[6] EFAVALEUKIN ALFA IS A NOVEL IL-2 MUTEIN THAT SELECTIVELY EXPANDS REGULATORY T CELLS: PHASE 1 RESULTS AND RATIONALE FOR CLINICAL INVESTIGATION IN ULCERATIVE COLITIS
Firoozbakht, Farshid
Tchao, Nadia
Sarkar, Nandita
Gorski, Kevin
Hu, Xuguang
Rauter, Ingrid
Rossi, Claudia Pena
GASTROENTEROLOGY, 2022, 162 (07) : S977 - S977
[7] Results from a First-in-Human Study with Bnz-1: A Novel Peptide Inhibitor of IL-2, IL9 and IL-15 for the Treatment of T-Cell Malignancies That Safely and Selectively Decreases Regulatory T-Cells, Natural Killer Cells, and CD8+ Central Memory T-Cells
Frohna, Paul
Tagaya, Yutaka
Ratnayake, Anoshie
Doerr, Nick
Basheer, Asjad
Al-Mawsawi, Laith
Kim, Woo Jae
Zapata, Juan
Wu, Xisorong
Azimi, Nazli
BLOOD, 2017, 130
[8] Preliminary results from an open-label, multicenter phase 1/2 dose escalation and expansion study of THOR-707, a novel not-Alpha IL-2, as a single agent in adult subjects with advanced or metastatic solid tumors
Janku, F.
Abdul-Karim, R.
Azad, A.
Bendell, J.
Gan, H.
Sen, S.
Tan, T.
Wang, J.
Marina, N.
Baker, L.
Ma, L.
Mooney, J.
Luo, D.
Leveque, J.
Milla, M.
Meniawy, T.
EUROPEAN JOURNAL OF CANCER, 2020, 138 : S11 - S11

← 1 →